glp-1 cardiovascular outcomes news Effects and Tolerability of Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients Cardiovascular, Kidney, and Safety Outcomes

1 (download XLSX Excel workbook with raw data Source Data Fig

doi: 10.7759/cureus.31313 565 Sharifi-RadJRodriguesCFStojanovi-RadiZDimitrijeviMAleksiANeffe-SkociskaKet al

20:133-141 [PubMed: 30499733] 371

Limitations of Clinical Trials (relevant for setting expectations): Highly selected participants (extensive exclusion criteria) Regular monitoring and support (monthly visits) Free medication (eliminates cost/access barriers) Intensive lifestyle interventions (may exceed real-world adherence) Short duration (68-72 weeks) relative to chronic disease treatment needs Real-World Studies Findings : According to real-world evidence published in peer-reviewed journals examining semaglutide and tirzepatide use in routine clinical practice: Weight loss magnitude is generally lower than clinical trial averages Discontinuation rates are often higher due to side effects, cost, or access issues Adherence rates vary widely (50-80% at 12 months in various studies) Weight regain after discontinuation is common Cardiovascular and metabolic benefits are observed even with modest weight loss Clinical Data Interpretation: Clinical trial results represent average outcomes under ideal conditions

Were also seeing rapid growth in multi-agonist therapies that expand beyond traditional single-target approaches

The first is the rational design approach exemplified by the Computed Helical Antimembrane Protein (CHAMP) method, developed by William F